1.McIntyre, RS. A vision for drug discovery and development: Novel targets and multilateral partnerships. Adv Ther. 2014; 31(3): 245–246.
2.Wen, Z, Christian, KM, Song, H, et al. Modeling psychiatric disorders with patient-derived iPSCs. Curr Opin Neurobiol. 2016; 36: 118–127.
3.O’shea, KS, McInnis, MG. Neurodevelopmental origins of bipolar disorder: iPSC models. Mol Cell Neurosci. 2016; 73: 63–83.
4.Villa, RF, Ferrari, F, Bagini, L, et al. Mitochondrial energy metabolism of rat hippocampus after treatment with the antidepressants desipramine and fluoxetine. Neuropharmacology. 2017; 121: 30–38.
5.Srivastava, R, Faust, T, Ramos, A, et al. Dynamic changes of the mitochondria in psychiatric illnesses: New mechanistic insights from human neuronal models. Biol Psychiatry. 2018; 83: 751–760. doi: 10.1016/j.biopsych.2018.01.007.
6.Pietruczuk, K, Lisowska, KA, Grabowski, K, et al. Proliferation and apoptosis of T lymphocytes in patients with bipolar disorder. Sci Rep. 2018; 8(1): 3327.
7.Neth, BJ, Craft, S. Insulin resistance and Alzheimer’s disease: Bioenergetic linkages. Front Aging Neurosci. 2017; 9: 345.
8.Zheng, K, Wang, N, Shen, Y, et al. Pro-apoptotic effects of microRNA-365 on retinal neurons by targeting IGF-1 in diabetic rats: An in vivo and in vitro study. J Diabetes Investig. 2018; 9(5): 1041–1051. doi: 10.1111/jdi.12815.
9.Kalaivani, A, Uddandrao, VS, Parim, B, et al. Reversal of high fat diet-induced obesity through modulating lipid metabolic enzymes and inflammatory markers expressions in rats. Arch Physiol Biochem. 2018; 124: 1–7.
10.Mansur, RB, Brietzke, E, McIntyre, RS. Is there a ‘metabolic-mood syndrome’? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015; 52: 89–104.
11.Mansur, RB, Lee, Y, Zhou, AJ, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Ann Clin Psychiatry. 2018; 30(1): 38–50.
12.McIntyre, RS, Soczynska, JK, Konarski, JZ, et al. Should depressive syndromes be reclassified as ‘metabolic syndrome type II’? Ann Clin Psychiatry. 2007; 19(4): 257–264.
13.Skvarc, DR, Dean, OM, Byrne, LK, et al. The effect of N-acetylcysteine (NAC) on human cognition – A systematic review. Neurosci Biobehav Rev. 2017; 78: 44–56.
14.Sa-Nguanmoo, P, Tanajak, P, Kerdphoo, S, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017; 333: 43–50.
15.Colle, R, de Larminat, D, Rotenberg, S, et al. Pioglitazone could induce remission in major depression: A meta-analysis. Neuropsychiatr Dis Treat. 2017; 13: 9–16.
16.Colle, R, de Larminat, D, Rotenberg, S, et al. PPAR-γ agonists for the treatment of major depression: A review. Pharmacopsychiatry. 2017; 50(2): 49–55.
17.McIntyre, RS, Soczynska, JK, Woldeyohannes, HO, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012; 14(7): 697–706.
18.Craft, S, Claxton, A, Baker, LD, et al. Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: A pilot clinical trial. J Alzheimer Dis. 2017; 57(4): 1325–1334.
19.Claxton, A, Baker, L, Hanson, A, et al. Long-acting intranasal insulin detemir improves working memory for adults with mild cognitive impairment or early-stage Alzheimer’s dementia. Alzheimers Dementia: J Alzheimers Assoc. 2013; 9(4): P657.
20.Mansur, RB, Ahmed, J, Cha, DS, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. J Affect Disord. 2017; 207: 114–120.
21.Mansur, RB, Lee, Y, Subramaniapillai, M, et al. Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology. 2018; 136: 335–342. doi: 10.1016/j.neuropharm.2018.01.048.
22.Phillips, AG, Geyer, MA, Robbins, TW. Effective use of animal models for therapeutic development in psychiatric and substance use disorders. Biol Psychiatry. 2018; 83: 915–923. doi: 10.1016/j.biopsych.2018.01.014.